Research Use Only. The information on this page summarizes published peptide research for laboratory and educational reference. The compounds discussed are intended exclusively for in vitro and non-clinical research. Nothing on this page constitutes medical advice or describes human use, diagnosis, treatment, or therapeutic application.
Overview
What is Ipamorelin? It is a synthetic pentapeptide ghrelin receptor agonist developed by Novo Nordisk in the late 1990s and first characterized in the published research literature in 1998. The compound is the reference selective growth hormone secretagogue in the ghrelin receptor agonist class, distinguished from related compounds by a notably clean pharmacological profile in which growth hormone release is stimulated without the cortisol and prolactin elevations characteristic of earlier ghrelin agonists.
The selectivity profile is what defines Ipamorelin in the published literature and what makes the compound a useful tool for ghrelin receptor pharmacology research. Most ghrelin agonists in the broader literature, including GHRP-2, GHRP-6, and hexarelin, produce measurable cortisol and prolactin spikes alongside growth hormone release. Ipamorelin does not, or does so only at concentrations well above those required for full GH-releasing activity. The cleaner endocrine signal allows experimental designs that isolate growth hormone effects from the broader hypothalamic-pituitary-adrenal axis perturbations that confound interpretation of GHRP-2 and hexarelin research.
The biological activity profile that defines Ipamorelin in the published literature depends on the specific five-amino-acid sequence with two non-natural amino acid residues and the C-terminal amidation that stabilizes the peptide against carboxypeptidase clearance. Synthesis errors at the non-natural amino acid positions can produce contaminants that retain the correct total mass but have substantially altered receptor binding, in ways that phenotypic readouts do not detect. The line between research-grade peptide commerce and gray-market pharmaceutical distribution runs through this verification step, since an Ipamorelin preparation whose sequence is not independently confirmed at each non-natural residue position cannot be assumed to behave like the Ipamorelin characterized across the published ghrelin receptor pharmacology literature.
This article covers what Ipamorelin is at the structural and biochemical level, the ghrelin receptor pharmacology and downstream signaling, the basis for the selectivity profile that distinguishes Ipamorelin from related compounds, the model systems most commonly used for Ipamorelin work, and the methodology considerations that govern rigorous in vitro and pre-clinical research with the compound. It sits within the GENEVIUM Research Hub coverage of growth hormone axis peptide research, in the Healing & Sleep pillar. The broader category context is treated in the Recovery Peptide Research overview, the dedicated parallel comparison to the GHRH receptor agonist CJC-1295 is covered in CJC-1295 vs Ipamorelin Research Comparison, and the CJC-1295 single-compound overview is treated in What Is CJC-1295?. For the broader research-use-only framework that governs all GENEVIUM peptides, see What Research Use Only Means.
What Is Ipamorelin at the Molecular Level
Ipamorelin is a synthetic pentapeptide consisting of five amino acid residues with deliberate substitution of non-natural amino acids and D-isomer residues at four of the five positions. The structural design is engineered to produce high affinity for the ghrelin receptor combined with metabolic stability against the proteases that rapidly clear native ghrelin and earlier-generation growth hormone secretagogues.
Origin and Development
Ipamorelin was developed at Novo Nordisk as part of a broader growth hormone secretagogue research program in the 1990s. The foundational characterization paper by Raun and colleagues, published in the European Journal of Endocrinology in 1998, established Ipamorelin as the first selective growth hormone secretagogue and reported the receptor-binding, GH-releasing, and endocrine-selectivity properties that have defined the compound across the subsequent research literature. The development goal at Novo Nordisk was a clean ghrelin receptor pharmacological tool, not a clinical product, and Ipamorelin has remained primarily a research compound rather than progressing to an approved clinical indication.
Sequence and Non-Natural Amino Acids
The Ipamorelin sequence is Aib-His-D-2-Nal-D-Phe-Lys with C-terminal amidation, written compactly as Aib-His-D-2-Nal-D-Phe-Lys-NH2. The five residues include three non-natural or non-standard structural elements that are critical for biological activity.
Position 1 is α-aminoisobutyric acid (Aib), a non-proteinogenic amino acid that confers helical conformation stability and resistance to aminopeptidase cleavage at the N-terminus. Position 3 is D-2-naphthylalanine (D-2-Nal), a bulky aromatic amino acid with the D-stereochemistry that contributes to ghrelin receptor binding affinity. Position 4 is D-phenylalanine, another D-isomer aromatic residue. The C-terminus is amidated rather than carboxylated, which blocks carboxypeptidase clearance and is one of the standard modifications used to stabilize bioactive peptides for research applications.
The non-natural amino acids and D-isomers are what allow Ipamorelin to retain activity in vivo over a useful pharmacological window. Native peptides composed entirely of standard L-amino acids would be cleared in minutes by peptidases. Ipamorelin has a published functional half-life of approximately two hours, short by pharmaceutical standards but more than adequate for the pulsatile GH-release pharmacology the compound is designed to produce.
Synthesis and Stability
Ipamorelin is produced by solid-phase peptide synthesis using standard fluorenylmethoxycarbonyl (Fmoc) chemistry, with the non-natural Aib and D-2-Nal residues supplied as protected Fmoc-amino acid building blocks. The peptide is purified by reverse-phase HPLC to research-grade purity standards (typically minimum 99% by reverse-phase HPLC) and characterized by mass spectrometry to confirm sequence identity. C-terminal amidation is introduced during synthesis using an appropriate amide resin and is verified by mass spectrometry as part of routine quality control.
Solubility in aqueous research buffers is good. Standard reconstitution uses bacteriostatic water, and reconstituted Ipamorelin retains stability at refrigerator temperatures over the time course of typical research experiments. Long-term storage of lyophilized Ipamorelin is at minus 20 degrees Celsius or lower in dry conditions. Repeated freeze-thaw cycles should be avoided.
Proposed Mechanisms of Action
The mechanistic identity of Ipamorelin is rooted in ghrelin receptor pharmacology. The compound is a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the physiological target of the endogenous orexigenic hormone ghrelin. Activation of this receptor in pituitary somatotrophs drives growth hormone release through a calcium-mobilization signaling pathway distinct from the cAMP signaling driven by GHRH receptor activation.
Ghrelin Receptor Binding
The growth hormone secretagogue receptor (GHS-R1a) is a class A G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland, as well as in hypothalamic regions involved in appetite regulation and several peripheral tissues. The receptor is the target of endogenous ghrelin, a 28-amino-acid peptide hormone produced primarily by gastric mucosal cells that drives both GH release and appetite. Ipamorelin binds the GHS-R1a with high affinity and produces full agonist activation, but does not engage the appetite-stimulating actions of ghrelin to the same degree, possibly because of differential signaling bias or different downstream receptor coupling in peripheral versus central nervous system locations.
Calcium Signaling and Growth Hormone Release
GHS-R1a activation triggers a Gαq-coupled signaling cascade producing phospholipase C activation, which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 binds receptors on the endoplasmic reticulum and triggers calcium release into the cytosol. The resulting calcium signal drives growth hormone release from pre-stored somatotroph secretory granules through calcium-dependent exocytosis.
The signaling pathway is mechanistically distinct from the cAMP-protein kinase A pathway driven by GHRH receptor activation. The two pathways converge on growth hormone release as the terminal endpoint, but they engage different intracellular signaling machinery and produce additive or synergistic GH release when activated simultaneously. This dual-pathway convergence on a common endpoint is the mechanistic basis for parallel-arm and combination research with CJC-1295 and Ipamorelin.
The Selectivity Profile
The defining pharmacological feature of Ipamorelin in the published research literature is selectivity. Earlier-generation ghrelin agonists, including GHRP-2, GHRP-6, and hexarelin, drive growth hormone release at low concentrations but also produce significant elevations in cortisol, prolactin, and adrenocorticotropic hormone (ACTH) at concentrations not far above those required for GH release. The clinical-pharmacology consequence is that experimental designs using GHRP-2 or hexarelin cannot cleanly isolate GH-axis effects from broader hypothalamic-pituitary-adrenal axis perturbations.
Ipamorelin produces full GH-releasing activity at concentrations that have minimal effect on cortisol, prolactin, and ACTH. The Raun 1998 foundational paper established this profile, and subsequent research across multiple laboratories has confirmed the selectivity across model systems. The mechanistic basis for the selectivity is not fully resolved, but the working hypothesis treats it as a consequence of differential signaling bias at the GHS-R1a receptor combined with reduced cross-reactivity at related receptors that mediate the off-target endocrine effects of less selective agonists.
The selectivity is what makes Ipamorelin valuable as a research tool. Other ghrelin agonists work; they just work less cleanly, and the additional endocrine confounds compress the experimental design space available to researchers studying GH-specific effects.
Areas of Active Ipamorelin Research
Several distinct research areas use Ipamorelin as a primary investigational compound. Each is characterized by its own model systems and endpoints, and researchers new to Ipamorelin work benefit from understanding which areas have the strongest published evidence base.
The foundational Ipamorelin research literature focuses on the pharmacological profile of selective GH release without confounding endocrine perturbations. The Raun 1998 paper and subsequent work from Johansen and colleagues characterized the dose-response relationship for GH release, the absence of significant cortisol and prolactin elevation across the active dosing range, and the receptor-binding kinetics that distinguish Ipamorelin from related ghrelin agonists. This body of work establishes Ipamorelin as the cleanest tool compound in the ghrelin receptor agonist class for research designed to isolate GH-specific effects.
Parallel-Arm Research with GHRH Receptor Agonists
Ipamorelin is most commonly studied alongside CJC-1295, the long-acting GHRH receptor agonist, in parallel-arm research designs investigating combined or comparative effects of the two growth hormone secretagogue pathways. The mechanistic rationale is that the two compounds activate distinct upstream signaling pathways (calcium mobilization for Ipamorelin, cAMP signaling for CJC-1295) that converge on growth hormone release, allowing experimental designs that quantitatively dissect the relative contribution of each pathway.
GH-IGF-1 Axis Research
Beyond direct GH release pharmacology, Ipamorelin has been used as a tool compound for broader GH-IGF-1 axis research. The downstream effects of pulsatile GH release on hepatic IGF-1 production, on IGF binding protein expression, and on the systemic anabolic markers of GH-axis activation are studied in both clinical research and pre-clinical animal models. The short half-life of Ipamorelin makes the compound suitable for research designs requiring discrete GH pulses rather than sustained GH elevation.
Bone Metabolism and GH Effects on Bone
A smaller research line examines Ipamorelin effects on bone metabolism, particularly in the context of glucocorticoid-induced osteopenia models. The rationale connects the GH-IGF-1 axis to osteoblast activity, with Ipamorelin used as a reproducible stimulus for endogenous GH release in animal models of bone biology research.
Research Methodology and Quality Standards
Ipamorelin research is sensitive to compound purity and identity confirmation, with particular attention required at the non-natural amino acid positions. Synthesis errors at position 1 (Aib) or position 3 (D-2-Nal) can produce contaminants that retain the correct total molecular mass but have substantially altered receptor binding profiles. Mass spectrometry alone cannot fully distinguish a correctly synthesized Ipamorelin from a contaminant with substituted natural amino acids at these positions, since the mass difference is small and falls within typical instrument tolerance. Sequence verification through amino acid analysis or high-resolution mass spectrometry with fragmentation is the more rigorous approach for confirming the non-natural residue integrity.
Published research consistently uses minimum 99% purity by reverse-phase HPLC, with mass spectrometric identity confirmation matching the theoretical molecular weight, as the standard threshold for ghrelin receptor agonist research. The C-terminal amidation should be verified by mass spectrometry (the amidated form is one mass unit lighter than the unamidated carboxylic acid form), since failure to amidate during synthesis is a recurring synthesis quality issue with bioactive peptides.
Reconstitution methodology should be standardized within and across studies. Bacteriostatic water is the most common reconstitution medium. The final concentration and the time elapsed between reconstitution and use should be reported in published research, since stability over hours to days at refrigerator temperature is good but not unlimited. Repeated freeze-thaw cycles should be avoided. For a detailed treatment of lyophilization, storage temperatures, and quality indicators researchers use to assess lyophilized peptide material before reconstitution, see Lyophilized Peptides: Methodology and Stability. For the analytical chemistry behind HPLC peptide verification, including detection wavelength choice and impurity profiling, see HPLC Peptide Verification.
Standard model systems for Ipamorelin research include in vivo rodent endocrinology preparations for pharmacokinetic and pharmacodynamic characterization, in vitro pituitary cell preparations for direct GHS-R1a signaling readouts, and clinical pharmacology designs for the human GH-release profile. GH release into the systemic circulation is the primary readout for most Ipamorelin research, with cortisol and prolactin measurement included specifically to confirm the selectivity profile rather than to detect off-target effects. The short pharmacological half-life means that timing of sample collection relative to administration is critical for capturing peak GH release.
GENEVIUM publishes a batch-specific Certificate of Analysis for every research peptide and makes them retrievable by batch number on the COA Lookup Page.
The selective ghrelin receptor pharmacology that distinguishes Ipamorelin in the published literature only holds for material whose five-amino-acid sequence, non-natural amino acid integrity, and C-terminal amidation are analytically confirmed on each batch. A supplier that documents sequence purity, mass-spectrometric identity, and non-natural residue verification on a batch-specific Certificate of Analysis retrievable by lot number is operating on the research-grade side of the line between legitimate research peptide commerce and gray-market pharmaceutical distribution. A supplier that ships Ipamorelin under generic purity claims without confirming integrity at the non-natural residue positions, or that aggregates purity across batches without lot-level documentation, is not, regardless of the headline purity figure displayed at point of sale.
Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide ghrelin receptor agonist developed by Novo Nordisk in the late 1990s and first characterized in the published research literature in 1998. The compound is the reference selective growth hormone secretagogue in the ghrelin receptor agonist class, distinguished by a clean pharmacological profile in which growth hormone release is stimulated without the cortisol and prolactin elevations characteristic of earlier ghrelin agonists like GHRP-2, GHRP-6, and hexarelin.
What is the Ipamorelin amino acid sequence?
The sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a five-residue peptide with C-terminal amidation. Three of the five positions use non-natural or non-standard amino acid residues: α-aminoisobutyric acid (Aib) at position 1, D-2-naphthylalanine (D-2-Nal) at position 3, and D-phenylalanine at position 4. These structural choices confer protease resistance and contribute to the high affinity for the ghrelin receptor that defines the compound pharmacological profile.
Why is Ipamorelin described as a selective growth hormone secretagogue?
The selectivity refers to the absence of significant cortisol, prolactin, and ACTH elevation alongside the growth hormone release driven by Ipamorelin administration. Other ghrelin receptor agonists in the published literature produce measurable spikes in these other hormones at concentrations near those required for GH release, which confounds experimental designs that aim to isolate GH-specific effects. Ipamorelin produces full GH-releasing activity at concentrations that have minimal effect on the broader hypothalamic-pituitary-adrenal axis, making it a cleaner tool compound for GH-specific research.
What model systems are most commonly used in Ipamorelin research?
In vivo rodent endocrinology preparations dominate the pre-clinical Ipamorelin research literature, with focus on growth hormone pulsatile release, IGF-1 axis dynamics, and parallel-arm methodology with GHRH receptor agonists like CJC-1295. Clinical pharmacology research in healthy adults has characterized the human GH-release profile and confirmed the selectivity against cortisol and prolactin elevation. In vitro pituitary cell preparations are used for direct GHS-R1a signaling readouts and dose-response characterization.
What Is Ipamorelin? Ghrelin Agonist Research
What Is Ipamorelin? Ghrelin Agonist Research
Overview
What is Ipamorelin? It is a synthetic pentapeptide ghrelin receptor agonist developed by Novo Nordisk in the late 1990s and first characterized in the published research literature in 1998. The compound is the reference selective growth hormone secretagogue in the ghrelin receptor agonist class, distinguished from related compounds by a notably clean pharmacological profile in which growth hormone release is stimulated without the cortisol and prolactin elevations characteristic of earlier ghrelin agonists.
The selectivity profile is what defines Ipamorelin in the published literature and what makes the compound a useful tool for ghrelin receptor pharmacology research. Most ghrelin agonists in the broader literature, including GHRP-2, GHRP-6, and hexarelin, produce measurable cortisol and prolactin spikes alongside growth hormone release. Ipamorelin does not, or does so only at concentrations well above those required for full GH-releasing activity. The cleaner endocrine signal allows experimental designs that isolate growth hormone effects from the broader hypothalamic-pituitary-adrenal axis perturbations that confound interpretation of GHRP-2 and hexarelin research.
The biological activity profile that defines Ipamorelin in the published literature depends on the specific five-amino-acid sequence with two non-natural amino acid residues and the C-terminal amidation that stabilizes the peptide against carboxypeptidase clearance. Synthesis errors at the non-natural amino acid positions can produce contaminants that retain the correct total mass but have substantially altered receptor binding, in ways that phenotypic readouts do not detect. The line between research-grade peptide commerce and gray-market pharmaceutical distribution runs through this verification step, since an Ipamorelin preparation whose sequence is not independently confirmed at each non-natural residue position cannot be assumed to behave like the Ipamorelin characterized across the published ghrelin receptor pharmacology literature.
This article covers what Ipamorelin is at the structural and biochemical level, the ghrelin receptor pharmacology and downstream signaling, the basis for the selectivity profile that distinguishes Ipamorelin from related compounds, the model systems most commonly used for Ipamorelin work, and the methodology considerations that govern rigorous in vitro and pre-clinical research with the compound. It sits within the GENEVIUM Research Hub coverage of growth hormone axis peptide research, in the Healing & Sleep pillar. The broader category context is treated in the Recovery Peptide Research overview, the dedicated parallel comparison to the GHRH receptor agonist CJC-1295 is covered in CJC-1295 vs Ipamorelin Research Comparison, and the CJC-1295 single-compound overview is treated in What Is CJC-1295?. For the broader research-use-only framework that governs all GENEVIUM peptides, see What Research Use Only Means.
What Is Ipamorelin at the Molecular Level
Ipamorelin is a synthetic pentapeptide consisting of five amino acid residues with deliberate substitution of non-natural amino acids and D-isomer residues at four of the five positions. The structural design is engineered to produce high affinity for the ghrelin receptor combined with metabolic stability against the proteases that rapidly clear native ghrelin and earlier-generation growth hormone secretagogues.
Origin and Development
Ipamorelin was developed at Novo Nordisk as part of a broader growth hormone secretagogue research program in the 1990s. The foundational characterization paper by Raun and colleagues, published in the European Journal of Endocrinology in 1998, established Ipamorelin as the first selective growth hormone secretagogue and reported the receptor-binding, GH-releasing, and endocrine-selectivity properties that have defined the compound across the subsequent research literature. The development goal at Novo Nordisk was a clean ghrelin receptor pharmacological tool, not a clinical product, and Ipamorelin has remained primarily a research compound rather than progressing to an approved clinical indication.
Sequence and Non-Natural Amino Acids
The Ipamorelin sequence is Aib-His-D-2-Nal-D-Phe-Lys with C-terminal amidation, written compactly as Aib-His-D-2-Nal-D-Phe-Lys-NH2. The five residues include three non-natural or non-standard structural elements that are critical for biological activity.
Position 1 is α-aminoisobutyric acid (Aib), a non-proteinogenic amino acid that confers helical conformation stability and resistance to aminopeptidase cleavage at the N-terminus. Position 3 is D-2-naphthylalanine (D-2-Nal), a bulky aromatic amino acid with the D-stereochemistry that contributes to ghrelin receptor binding affinity. Position 4 is D-phenylalanine, another D-isomer aromatic residue. The C-terminus is amidated rather than carboxylated, which blocks carboxypeptidase clearance and is one of the standard modifications used to stabilize bioactive peptides for research applications.
The non-natural amino acids and D-isomers are what allow Ipamorelin to retain activity in vivo over a useful pharmacological window. Native peptides composed entirely of standard L-amino acids would be cleared in minutes by peptidases. Ipamorelin has a published functional half-life of approximately two hours, short by pharmaceutical standards but more than adequate for the pulsatile GH-release pharmacology the compound is designed to produce.
Synthesis and Stability
Ipamorelin is produced by solid-phase peptide synthesis using standard fluorenylmethoxycarbonyl (Fmoc) chemistry, with the non-natural Aib and D-2-Nal residues supplied as protected Fmoc-amino acid building blocks. The peptide is purified by reverse-phase HPLC to research-grade purity standards (typically minimum 99% by reverse-phase HPLC) and characterized by mass spectrometry to confirm sequence identity. C-terminal amidation is introduced during synthesis using an appropriate amide resin and is verified by mass spectrometry as part of routine quality control.
Solubility in aqueous research buffers is good. Standard reconstitution uses bacteriostatic water, and reconstituted Ipamorelin retains stability at refrigerator temperatures over the time course of typical research experiments. Long-term storage of lyophilized Ipamorelin is at minus 20 degrees Celsius or lower in dry conditions. Repeated freeze-thaw cycles should be avoided.
Proposed Mechanisms of Action
The mechanistic identity of Ipamorelin is rooted in ghrelin receptor pharmacology. The compound is a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the physiological target of the endogenous orexigenic hormone ghrelin. Activation of this receptor in pituitary somatotrophs drives growth hormone release through a calcium-mobilization signaling pathway distinct from the cAMP signaling driven by GHRH receptor activation.
Ghrelin Receptor Binding
The growth hormone secretagogue receptor (GHS-R1a) is a class A G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland, as well as in hypothalamic regions involved in appetite regulation and several peripheral tissues. The receptor is the target of endogenous ghrelin, a 28-amino-acid peptide hormone produced primarily by gastric mucosal cells that drives both GH release and appetite. Ipamorelin binds the GHS-R1a with high affinity and produces full agonist activation, but does not engage the appetite-stimulating actions of ghrelin to the same degree, possibly because of differential signaling bias or different downstream receptor coupling in peripheral versus central nervous system locations.
Calcium Signaling and Growth Hormone Release
GHS-R1a activation triggers a Gαq-coupled signaling cascade producing phospholipase C activation, which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 binds receptors on the endoplasmic reticulum and triggers calcium release into the cytosol. The resulting calcium signal drives growth hormone release from pre-stored somatotroph secretory granules through calcium-dependent exocytosis.
The signaling pathway is mechanistically distinct from the cAMP-protein kinase A pathway driven by GHRH receptor activation. The two pathways converge on growth hormone release as the terminal endpoint, but they engage different intracellular signaling machinery and produce additive or synergistic GH release when activated simultaneously. This dual-pathway convergence on a common endpoint is the mechanistic basis for parallel-arm and combination research with CJC-1295 and Ipamorelin.
The Selectivity Profile
The defining pharmacological feature of Ipamorelin in the published research literature is selectivity. Earlier-generation ghrelin agonists, including GHRP-2, GHRP-6, and hexarelin, drive growth hormone release at low concentrations but also produce significant elevations in cortisol, prolactin, and adrenocorticotropic hormone (ACTH) at concentrations not far above those required for GH release. The clinical-pharmacology consequence is that experimental designs using GHRP-2 or hexarelin cannot cleanly isolate GH-axis effects from broader hypothalamic-pituitary-adrenal axis perturbations.
Ipamorelin produces full GH-releasing activity at concentrations that have minimal effect on cortisol, prolactin, and ACTH. The Raun 1998 foundational paper established this profile, and subsequent research across multiple laboratories has confirmed the selectivity across model systems. The mechanistic basis for the selectivity is not fully resolved, but the working hypothesis treats it as a consequence of differential signaling bias at the GHS-R1a receptor combined with reduced cross-reactivity at related receptors that mediate the off-target endocrine effects of less selective agonists.
The selectivity is what makes Ipamorelin valuable as a research tool. Other ghrelin agonists work; they just work less cleanly, and the additional endocrine confounds compress the experimental design space available to researchers studying GH-specific effects.
Areas of Active Ipamorelin Research
Several distinct research areas use Ipamorelin as a primary investigational compound. Each is characterized by its own model systems and endpoints, and researchers new to Ipamorelin work benefit from understanding which areas have the strongest published evidence base.
Selective Growth Hormone Secretagogue Pharmacology
The foundational Ipamorelin research literature focuses on the pharmacological profile of selective GH release without confounding endocrine perturbations. The Raun 1998 paper and subsequent work from Johansen and colleagues characterized the dose-response relationship for GH release, the absence of significant cortisol and prolactin elevation across the active dosing range, and the receptor-binding kinetics that distinguish Ipamorelin from related ghrelin agonists. This body of work establishes Ipamorelin as the cleanest tool compound in the ghrelin receptor agonist class for research designed to isolate GH-specific effects.
Parallel-Arm Research with GHRH Receptor Agonists
Ipamorelin is most commonly studied alongside CJC-1295, the long-acting GHRH receptor agonist, in parallel-arm research designs investigating combined or comparative effects of the two growth hormone secretagogue pathways. The mechanistic rationale is that the two compounds activate distinct upstream signaling pathways (calcium mobilization for Ipamorelin, cAMP signaling for CJC-1295) that converge on growth hormone release, allowing experimental designs that quantitatively dissect the relative contribution of each pathway.
GH-IGF-1 Axis Research
Beyond direct GH release pharmacology, Ipamorelin has been used as a tool compound for broader GH-IGF-1 axis research. The downstream effects of pulsatile GH release on hepatic IGF-1 production, on IGF binding protein expression, and on the systemic anabolic markers of GH-axis activation are studied in both clinical research and pre-clinical animal models. The short half-life of Ipamorelin makes the compound suitable for research designs requiring discrete GH pulses rather than sustained GH elevation.
Bone Metabolism and GH Effects on Bone
A smaller research line examines Ipamorelin effects on bone metabolism, particularly in the context of glucocorticoid-induced osteopenia models. The rationale connects the GH-IGF-1 axis to osteoblast activity, with Ipamorelin used as a reproducible stimulus for endogenous GH release in animal models of bone biology research.
Research Methodology and Quality Standards
Ipamorelin research is sensitive to compound purity and identity confirmation, with particular attention required at the non-natural amino acid positions. Synthesis errors at position 1 (Aib) or position 3 (D-2-Nal) can produce contaminants that retain the correct total molecular mass but have substantially altered receptor binding profiles. Mass spectrometry alone cannot fully distinguish a correctly synthesized Ipamorelin from a contaminant with substituted natural amino acids at these positions, since the mass difference is small and falls within typical instrument tolerance. Sequence verification through amino acid analysis or high-resolution mass spectrometry with fragmentation is the more rigorous approach for confirming the non-natural residue integrity.
Published research consistently uses minimum 99% purity by reverse-phase HPLC, with mass spectrometric identity confirmation matching the theoretical molecular weight, as the standard threshold for ghrelin receptor agonist research. The C-terminal amidation should be verified by mass spectrometry (the amidated form is one mass unit lighter than the unamidated carboxylic acid form), since failure to amidate during synthesis is a recurring synthesis quality issue with bioactive peptides.
Reconstitution methodology should be standardized within and across studies. Bacteriostatic water is the most common reconstitution medium. The final concentration and the time elapsed between reconstitution and use should be reported in published research, since stability over hours to days at refrigerator temperature is good but not unlimited. Repeated freeze-thaw cycles should be avoided. For a detailed treatment of lyophilization, storage temperatures, and quality indicators researchers use to assess lyophilized peptide material before reconstitution, see Lyophilized Peptides: Methodology and Stability. For the analytical chemistry behind HPLC peptide verification, including detection wavelength choice and impurity profiling, see HPLC Peptide Verification.
Standard model systems for Ipamorelin research include in vivo rodent endocrinology preparations for pharmacokinetic and pharmacodynamic characterization, in vitro pituitary cell preparations for direct GHS-R1a signaling readouts, and clinical pharmacology designs for the human GH-release profile. GH release into the systemic circulation is the primary readout for most Ipamorelin research, with cortisol and prolactin measurement included specifically to confirm the selectivity profile rather than to detect off-target effects. The short pharmacological half-life means that timing of sample collection relative to administration is critical for capturing peak GH release.
GENEVIUM publishes a batch-specific Certificate of Analysis for every research peptide and makes them retrievable by batch number on the COA Lookup Page.
The selective ghrelin receptor pharmacology that distinguishes Ipamorelin in the published literature only holds for material whose five-amino-acid sequence, non-natural amino acid integrity, and C-terminal amidation are analytically confirmed on each batch. A supplier that documents sequence purity, mass-spectrometric identity, and non-natural residue verification on a batch-specific Certificate of Analysis retrievable by lot number is operating on the research-grade side of the line between legitimate research peptide commerce and gray-market pharmaceutical distribution. A supplier that ships Ipamorelin under generic purity claims without confirming integrity at the non-natural residue positions, or that aggregates purity across batches without lot-level documentation, is not, regardless of the headline purity figure displayed at point of sale.
Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide ghrelin receptor agonist developed by Novo Nordisk in the late 1990s and first characterized in the published research literature in 1998. The compound is the reference selective growth hormone secretagogue in the ghrelin receptor agonist class, distinguished by a clean pharmacological profile in which growth hormone release is stimulated without the cortisol and prolactin elevations characteristic of earlier ghrelin agonists like GHRP-2, GHRP-6, and hexarelin.
What is the Ipamorelin amino acid sequence?
The sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a five-residue peptide with C-terminal amidation. Three of the five positions use non-natural or non-standard amino acid residues: α-aminoisobutyric acid (Aib) at position 1, D-2-naphthylalanine (D-2-Nal) at position 3, and D-phenylalanine at position 4. These structural choices confer protease resistance and contribute to the high affinity for the ghrelin receptor that defines the compound pharmacological profile.
Why is Ipamorelin described as a selective growth hormone secretagogue?
The selectivity refers to the absence of significant cortisol, prolactin, and ACTH elevation alongside the growth hormone release driven by Ipamorelin administration. Other ghrelin receptor agonists in the published literature produce measurable spikes in these other hormones at concentrations near those required for GH release, which confounds experimental designs that aim to isolate GH-specific effects. Ipamorelin produces full GH-releasing activity at concentrations that have minimal effect on the broader hypothalamic-pituitary-adrenal axis, making it a cleaner tool compound for GH-specific research.
What model systems are most commonly used in Ipamorelin research?
In vivo rodent endocrinology preparations dominate the pre-clinical Ipamorelin research literature, with focus on growth hormone pulsatile release, IGF-1 axis dynamics, and parallel-arm methodology with GHRH receptor agonists like CJC-1295. Clinical pharmacology research in healthy adults has characterized the human GH-release profile and confirmed the selectivity against cortisol and prolactin elevation. In vitro pituitary cell preparations are used for direct GHS-R1a signaling readouts and dose-response characterization.